Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Precancerous Conditions 1Monoclonal Gammopathy of Undetermined Significance 1

Interventions

Peripheral Blood Stem Cell Transplantation 4Cyclophosphamide 4fludarabine phosphate 3Epoetin Alfa 3Darbepoetin alfa 3Whole-Body Irradiation 2Tacrolimus 2Mycophenolic Acid 2Morphine 2Microarray Analysis 2Methylprednisolone 2Interferon-alpha 2In Situ Hybridization, Fluorescence 2Filgrastim 2Cytogenetic Analysis 2Cyclosporine 2Carboplatin 2Busulfan 2Antilymphocyte Serum 2tanespimycin 1sargramostim 1pyroxamide 1ferrous sulfate 1ferric gluconate 1alethine 1aldesleukin 1Topotecan 1Therapeutics 1Tetradecanoylphorbol Acetate 1Sucrose 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Monoclonal Gammopathy of Undetermined Significance × Rituximab × Other neoplasm × Clear all
NCT00588822 2014-05-06

Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance

Mayo Clinic

Phase 2 Terminated
21 enrolled 11 charts
Other neoplasm

Monoclonal Gammopathy of Undetermined Significance, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡